Using data from the Surveillance, Epidemiology and End Results (SEER-18) database linked with Medicare files, Dr. The study, published in Cancer Medicine on Feb 8th, looked at a number of statin therapies, and metformin, an anti-diabetic medication, in high-risk prostate cancer populations. “Both metformin and statins have been associated with longer life in prostate cancer patients, yet because they are commonly prescribed together, no study we know of has looked at these two medications separately,” says senior author Grace Lu-Yao, PhD, associate director of Population Science at the Sidney Kimmel Cancer Center-Jefferson Health, one of only eight NCI-designated cancer centers nationwide with a prostate cancer program of excellence. New research shows that statins, alone or with metformin, increase survival in men with high-risk prostate cancer. However, it is unclear which of these two medications – commonly prescribed together - contributes the most and whether they can impact high-risk prostate cancer. Preliminary research suggests that two commonly prescribed medications, cholesterol-lowering statins and the diabetes therapy metformin may have anticancer effects. PHILADELPHIA – Among high-risk prostate cancer patients – those with high PSA and Gleason scores of 8 or more – many will develop a difficult-to-treat disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |